$6.7
+0.11
(+1.67%)▲
Insights on Clearpoint Neuro Inc
Revenue is down for the last 2 quarters, 5.95M → 5.76M (in $), with an average decrease of 3.2% per quarter
Netprofit is up for the last 2 quarters, -7.05M → -4.80M (in $), with an average increase of 46.6% per quarter
In the last 1 year, Boston Scientific Corp. has given 18.9% return, outperforming this stock by 44.2%
3.55%
Downside
Day's Volatility :4.26%
Upside
0.73%
39.55%
Downside
52 Weeks Volatility :63.18%
Upside
39.09%
Period | Clearpoint Neuro Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 25.0% | -0.7% | 0.0% |
6 Months | -7.07% | 1.3% | 0.0% |
1 Year | -22.63% | -4.3% | -1.5% |
3 Years | -63.71% | 18.3% | -7.5% |
Market Capitalization | 147.5M |
Book Value | $0.98 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.89 |
Wall Street Target Price | 9.5 |
Profit Margin | -97.92% |
Operating Margin TTM | -84.99% |
Return On Assets TTM | -27.33% |
Return On Equity TTM | -68.33% |
Revenue TTM | 22.3M |
Revenue Per Share TTM | 0.91 |
Quarterly Revenue Growth YOY | 12.0% |
Gross Profit TTM | 13.5M |
EBITDA | -21.7M |
Diluted Eps TTM | -0.89 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.93 |
EPS Estimate Next Year | -0.79 |
EPS Estimate Current Quarter | -0.25 |
EPS Estimate Next Quarter | -0.22 |
What analysts predicted
Upside of 41.79%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 7.4M | ↑ 28.35% |
Net Income | -7.2M | ↓ 11.18% |
Net Profit Margin | -97.12% | ↑ 43.24% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 7.4M | ↓ 0.36% |
Net Income | -6.2M | ↓ 14.01% |
Net Profit Margin | -83.82% | ↑ 13.3% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 11.2M | ↑ 52.54% |
Net Income | -6.5M | ↑ 5.53% |
Net Profit Margin | -57.98% | ↑ 25.84% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 12.8M | ↑ 14.37% |
Net Income | -9.1M | ↑ 40.04% |
Net Profit Margin | -71.0% | ↓ 13.02% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 16.3M | ↑ 27.05% |
Net Income | -15.3M | ↑ 68.2% |
Net Profit Margin | -93.99% | ↓ 22.99% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 20.6M | ↑ 26.09% |
Net Income | -16.5M | ↑ 7.95% |
Net Profit Margin | -80.47% | ↑ 13.52% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 5.2M | ↑ 3.36% |
Net Income | -4.4M | ↑ 8.58% |
Net Profit Margin | -84.65% | ↓ 4.07% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 5.1M | ↓ 1.04% |
Net Income | -3.8M | ↓ 14.11% |
Net Profit Margin | -73.47% | ↑ 11.18% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 5.2M | ↑ 0.54% |
Net Income | -4.3M | ↑ 13.75% |
Net Profit Margin | -83.13% | ↓ 9.66% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.4M | ↑ 5.01% |
Net Income | -5.4M | ↑ 25.37% |
Net Profit Margin | -99.25% | ↓ 16.12% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 6.0M | ↑ 9.52% |
Net Income | -7.1M | ↑ 30.79% |
Net Profit Margin | -118.52% | ↓ 19.27% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.8M | ↓ 3.16% |
Net Income | -4.8M | ↓ 31.81% |
Net Profit Margin | -83.46% | ↑ 35.06% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 13.9M | ↑ 87.78% |
Total Liabilities | 8.1M | ↓ 1.08% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 7.9M | ↓ 43.47% |
Total Liabilities | 6.3M | ↓ 21.35% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 11.9M | ↑ 51.8% |
Total Liabilities | 7.3M | ↑ 15.66% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 29.6M | ↑ 148.52% |
Total Liabilities | 27.3M | ↑ 271.44% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 65.6M | ↑ 121.26% |
Total Liabilities | 16.8M | ↓ 38.4% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 55.5M | ↓ 15.39% |
Total Liabilities | 18.6M | ↑ 10.77% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 60.2M | ↓ 2.47% |
Total Liabilities | 17.4M | ↑ 8.62% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 57.7M | ↓ 4.15% |
Total Liabilities | 17.9M | ↑ 2.53% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 55.5M | ↓ 3.89% |
Total Liabilities | 18.6M | ↑ 4.16% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 50.2M | ↓ 9.45% |
Total Liabilities | 17.7M | ↓ 5.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 47.6M | ↓ 5.19% |
Total Liabilities | 20.2M | ↑ 14.51% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 43.8M | ↓ 7.98% |
Total Liabilities | 19.7M | ↓ 2.41% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -6.0M | ↑ 2.96% |
Investing Cash Flow | -26.8K | ↓ 73.51% |
Financing Cash Flow | 12.0M | ↑ 213.28% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.6M | ↓ 22.73% |
Investing Cash Flow | -63.5K | ↑ 137.33% |
Financing Cash Flow | -1.5M | ↓ 112.46% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -2.8M | ↓ 38.46% |
Investing Cash Flow | -160.0K | ↑ 152.01% |
Financing Cash Flow | 5.6M | ↓ 474.97% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -7.8M | ↑ 174.01% |
Investing Cash Flow | -482.0K | ↑ 201.25% |
Financing Cash Flow | 22.7M | ↑ 304.92% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.7M | ↑ 62.62% |
Investing Cash Flow | -168.0K | ↓ 65.15% |
Financing Cash Flow | 46.9M | ↑ 106.56% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -16.2M | ↑ 27.33% |
Investing Cash Flow | -10.7M | ↑ 6290.48% |
Financing Cash Flow | 409.0K | ↓ 99.13% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.0M | ↑ 16.68% |
Investing Cash Flow | -21.7M | ↑ 11611.35% |
Financing Cash Flow | 513.0K | ↑ 17000.0% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.9M | ↓ 22.67% |
Investing Cash Flow | -631.0K | ↓ 97.09% |
Financing Cash Flow | -329.0K | ↓ 164.13% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.1M | ↓ 20.43% |
Investing Cash Flow | 11.7M | ↓ 1961.49% |
Financing Cash Flow | 222.0K | ↓ 167.48% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.7M | ↑ 85.32% |
Investing Cash Flow | -138.0K | ↓ 101.17% |
Financing Cash Flow | -5.0K | ↓ 102.25% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.1M | ↓ 10.65% |
Investing Cash Flow | 9.5M | ↓ 6991.3% |
Financing Cash Flow | 237.0K | ↓ 4840.0% |
Sell
Neutral
Buy
Clearpoint Neuro Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Clearpoint Neuro Inc | 46.61% | -7.07% | -22.63% | -63.71% | -63.71% |
![]() Stryker Corporation | 2.58% | 3.28% | 16.03% | 24.5% | 68.41% |
![]() Dexcom, Inc. | 18.93% | -7.83% | 0.16% | 34.56% | 280.3% |
![]() Boston Scientific Corp. | 2.31% | 7.32% | 16.59% | 63.54% | 50.3% |
![]() Abbott Laboratories | 9.1% | 3.07% | -4.55% | -2.35% | 45.48% |
![]() Medtronic Plc | 10.09% | -5.85% | -0.45% | -29.39% | -16.88% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Clearpoint Neuro Inc | NA | NA | NA | -0.93 | -0.68 | -0.27 | 0.0 | 0.98 |
![]() Stryker Corporation | 44.25 | 44.25 | 2.89 | 10.41 | 0.15 | 0.07 | 0.01 | 47.13 |
![]() Dexcom, Inc. | 128.52 | 128.52 | 2.39 | 1.43 | 0.18 | 0.06 | 0.0 | 5.87 |
![]() Boston Scientific Corp. | 68.46 | 68.46 | 1.75 | 2.01 | 0.07 | 0.04 | 0.02 | 12.89 |
![]() Abbott Laboratories | 35.67 | 35.67 | 25.14 | 4.44 | 0.14 | 0.06 | 0.02 | 21.59 |
![]() Medtronic Plc | 25.97 | 25.97 | 1.61 | 5.28 | 0.08 | 0.04 | 0.03 | 38.69 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Clearpoint Neuro Inc | Buy | $147.5M | -63.71% | NA | -97.92% |
![]() Stryker Corporation | Buy | $113.1B | 68.41% | 44.25 | 13.0% |
![]() Dexcom, Inc. | Buy | $45.1B | 280.3% | 128.52 | 11.08% |
![]() Boston Scientific Corp. | Buy | $82.2B | 50.3% | 68.46 | 8.93% |
![]() Abbott Laboratories | Buy | $182.1B | 45.48% | 35.67 | 12.92% |
![]() Medtronic Plc | Buy | $106.4B | -16.88% | 25.97 | 12.84% |
BlackRock Inc
Vanguard Group Inc
Geode Capital Management, LLC
Taylor Frigon Capital Management LLC
Brown Advisory Holdings Inc
State Street Corporation
Clearpoint Neuro Inc’s price-to-earnings ratio stands at None
Read Morewe are a medical device company that develops and commercializes innovative platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging, or mri, guidance. since our inception in 1998, we have focused on research and product development in the field of interventional mri. from 1998 to 2002, we deployed significant resources to fund our efforts to develop the foundational capabilities for enabling mri-guided interventions and to build an intellectual property position. in 2003, our focus shifted to identifying and building out commercial applications for the technologies we developed in prior years. we have two product platforms. our clearpoint® system, which is in commercial use in the united states, is used to perform minimally invasive surgical procedures in the brain. our cleartrace system, which is still in development, will be used to perform minimally invasive surgical procedures in the heart. bot
Organization | Clearpoint Neuro Inc |
Employees | 108 |
CEO | Mr. Joseph Michael Burnett |
Industry | Health Technology |
Asymmetric Smart Alpha S&p 500 Etf
$6.70
+1.67%
Advisorshares Alpha Dna Equity Sentiment Etf
$6.70
+1.67%
Falcon's Beyond Global Inc
$6.70
+1.67%
Jaguar Global Growth Corporation I
$6.70
+1.67%
Missfresh Ltd
$6.70
+1.67%
Shuaa Partners Acquisition Corp I
$6.70
+1.67%
Rose Hill Acquisition Corp
$6.70
+1.67%
Partners Bancorp
$6.70
+1.67%
Bsquare Corp
$6.70
+1.67%